Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New artificial cornea implant offers hope for patients with failed transplants

NCT ID NCT07344168

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a permanent artificial implant called EndoArt for people with long-term corneal swelling who have had multiple failed cornea transplants and cannot have another one. The implant acts as a barrier to stop fluid from entering the cornea. The study will check safety and whether it improves vision in 123 participants over 12 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 123 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Apr 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female subjects 30-85 years of age. 2. Have chronic corneal edema (lasting at least 3 months) and have experienced at least 3 prior keratoplasty (EK/PK) failures. 3. Is not a reasonable candidate for any form of corneal transplant, including penetrating keratoplasty. 4. CCT of 650-1200 μm, not including DSAEK thickness. \* In cases where the treated eye has undergone PKP, or if the corneal thickness of the contralateral eye cannot be measured (e.g., monocular patient, or if the contralateral eye has corneal edema or a history of PKP), the CCT of the study eye must be between 700-1200 μm. 5. Pseudophakia 6. Cornea WTW between 10-13 mm 7. IOP \<20 mmHg and IOP≥8 mmHg 8. BCVA of the study eye equal or worse than 0.50 LogMAR and up to 2.40 LogMAR (Hand motion is between 2.20-2.40 LogMAR). 9. Must have better visual acuity in the contralateral eye, which must be at least 0.20 LogMAR better than the treated eye and have a visual acuity of at least 1.00 LogMAR. 10. Central general clarity grade ≥2 (See Table 14. Central general clarity grading) 11. Willing and able to understand and sign informed consent prior to any study-related procedure. 12. Willing and able to follow study instructions (e.g., to lay on one's back for at least 4 hours post op.), able to self-administer or have caregiver available to administer eyedrops as required by the protocol for the duration of the study, and able to attend study visits/assessments for the duration of the study. Exclusion Criteria: 1. No light perception or light perception. 2. Opaque scar in the visual axis that is indicated for PKP. 3. Irregular posterior cornea (e.g. post trauma) in the 6.5 mm central part of the cornea (EndoArt® diameter). 4. Current infection of the cornea. 5. Central Band keratopathy and/or limbal stem cell deficiency. 6. Diagnosis of: Sjogren's Syndrome, GVHD. 7. PUK (peripheral ulcerative keratitis) 8. Phthisis bulbi or subject is at high risk of developing phthisis (Hypothony). 9. History of corneal refractive surgery: LASIK, PRK, SMILE, Epi-keratoplasty (or any anterior lamellar keratoplasty, inlays) and Radial Keratotomy (RK). 10. Severe corneal distortion e.g.: keratoconus, pellucid marginal degeneration or keratoglobus (not relevant post PKP). 11. Subject with medically uncontrolled intra ocular pressure, which requires surgical intervention. 12. Aphakia. 13. Active inflammation, or active, recurrent, or Chronic Uveitis 14. Dislocation or partial dislocation of the IOL. 15. Have large iris defect (more than 90 degrees) which could compromise intraoperative air bubble formation, excluding inferior defect. 16. Severe ptosis (middle of pupil or covering the pupil entirely). 17. Subject receiving regular intravitreal injection. 18. History of persistent/ recurrent corneal erosion or persistent epithelial defect with difficulties in epithelial re-growth (erosion more than 2 months). 19. History of ocular herpetic keratitis 20. Current retinal detachments 21. Advanced optic nerve cupping (defined as a cup-disc ratio of 0.9 or greater). 22. Posterior segment masses or other acute significant posterior segment pathology (e.g., active age-related macular degeneration or chronic cystoid macular edema). 23. Afferent Pupillary Defect (APD) 24. Fellow eye CCT \< 500 µm 25. Any other acute ocular condition 26. Bilateral implantation of the EndoArt® 27. Posterior vitrectomy (anterior vitrectomy is allowed) 28. Subjects with mental impairment 29. Subject with history of spontaneous corneal perforations. 30. Pregnant or lactating women, or with childbirth plans during the clinical trial 31. Currently participating or have participated in an investigational study, other than this study, within the past 60 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Corneal edema are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.